Andrew Cheng - 30 Aug 2023 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
President and CEO, Director
Signature
/s/ Jonathan Young, Attorney-in-Fact
Issuer symbol
AKRO
Transactions as of
30 Aug 2023
Net transactions value
+$9,225
Form type
4
Filing time
30 Aug 2023, 19:04:26 UTC
Previous filing
03 Aug 2023
Next filing
18 Sep 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Options Exercise $9,225 +15,000 +3.4% $0.6150* 462,680 30 Aug 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKRO Stock Option (Right to Buy) Options Exercise $0 -15,000 -13% $0.000000 102,212 30 Aug 2023 Common Stock 15,000 $0.6150 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options are vested and currently exercisable.